18085-76-2

Basic information

• Product Name: 3-chloro-N-(2,6-dimethylphenyl)propanamide
• Synonyms: 3-chloro-N-(2,6-dimethylphenyl)propanamide
• CAS NO: 18085-76-2
• Molecular Formula: C₁₁H₁₄ClNO
• Molecular Weight: 211.68796
• Mol File: 18085-76-2.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-chloro-N-(2,6-dimethylphenyl)propanamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-chloro-N-(2,6-dimethylphenyl)propanamide(18085-76-2)
• EPA Substance Registry System: 3-chloro-N-(2,6-dimethylphenyl)propanamide(18085-76-2)

Safety Data

• Hazardous Substances Data: 18085-76-2(Hazardous Substances Data)

Upstream product

• 625-36-5 2-chloropropionyl chloride 
• 87-62-7 2,6-dimethylaniline 
• 108-20-3 di-isopropyl ether 

Downstream Products

• 96080-96-5 N,N-dimethyl-β-alanine-(2,6-dimethyl-anilide) 
• 66675-75-0 N-(2,6-Dimethylphenyl)-3-aminopropanamide 
• 84243-42-5 2-methyl-1-[2-[(2,6-dimethylphenyl)carbamoyl]ethyl]-2-imidazoline 
• 105630-63-5 3-(dimethylaminopropylamino)-2',6'-dimethylpropionanilide 
• 1263764-80-2 C₁₄H₁₇N₃O 
• 4933-38-4 N-(2,6-dimethylphenyl)-3-(piperidin-1-yl)propanamide 
• 105642-38-4 3-(diethylaminopropylamino)-2',6'-dimethylpropionanilide 
• 71352-74-4 N-(2,6-Dimethyl-phenyl)-3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-propionamide 
• 21236-52-2 3-(diethylamino)-N-(2,6-dimethyl-phenyl)propionamide 

Relevant articles and documents

Method and using tracer charged ion channel

The invention provides compounds, compositions, methods, and kits for the treatment of pain, itch, and neurogenic inflammation.

Synthesis and antispasmodic activity of lidocaine derivatives endowed with reduced local anesthetic action

The present structure-activity relationship (SAR) study focused on chemical modifications of the structure of the local anesthetic lidocaine, and indicated analogues having reduced anesthetic potency, but with superior potency relative to the prototype in preventing anaphylactic or histamine-evoked ileum contraction. From the SAR analysis, 2-(diethylamino)-N-(trifluoromethyl-phenyl) and 2-(diethylamino)-N-(dimethyl-phenyl) acetamides were selected as the most promising compounds. New insights into the applicability of non-anesthetic lidocaine derivatives as templates in drug discovery for allergic syndromes are provided.

The synthesis and anticonvulsant activity of some omega-phthalimido-N-phenylacetamide and propionamide derivatives.

In this study, by combining anilide and N', N'-phthaloylglycinamide pharmacophores which are known to produce potent anticonvulsant compounds, sixteen omega-phthalimido-N-phenylacetamide and propionamide derivatives bearing substituents at positions 2 or 2, 6 on N-phenyl ring have been synthesized. The structural confirmation of the title compounds was achieved by interpretation of spectral and analytical data. The anticonvulsant activity of the title compounds was determined against maximal electroshock seizure at 100 mg/kg dose level in mice. The preliminary screening results indicated that omega-phthalimido-N-phenylacetamide and propionamide nuclei have pronounced anticonvulsant activity against maximal electroshock seizure.